| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited American Depositary Shares | Fremanezumab | Fibromyalgia | Phase 2 | Ongoing | Subcutaneous | Neurology |
| TFF Pharmaceuticals Inc - Ordinary Shares | Voriconazole Inhalation Powder (TFF VORI) | Asthma | Phase 2 | Ongoing | Inhalation | Respiratory |
| TFF Pharmaceuticals Inc - Ordinary Shares | TFF TAC (Tacrolimus Inhalation Powder) | Lung transplant (post) | Phase 2 | Data Released | Inhalation | Immunosuppressant |
| TFF Pharmaceuticals Inc - Ordinary Shares | Voriconazole Inhalation Powder - (VORI) | Invasive Pulmonary Aspergillosis (IPA) | Phase 2 | Data Released | Inhalation | Anti-Fungal |
| TG Therapeutics Inc. | UKONIQ (umbralisib) and ublituximab | Chronic Lymphocytic Leukemia (CLL) and small lymphocytic lymphoma (SLL) | BLA Filing | Withdrawn | Oral and intravenous | Oncology |
| TG Therapeutics Inc. | BRIUMVI (ublituximab-xiiy) - (ULTIMATE KIDS I) | Multiple Sclerosis | Phase 2 | Ongoing | Intravenous | Neurology |
| TherapeuticsMD Inc. | BIJUVA (estradiol and progesterone) - low dose | Vasomotor symptoms due to menopause | sNDA Filing | Oral | Women's Health | |
| Theravance Biopharma Inc. | Ampreloxetine - (CYPRESS) | Symptomatic neurogenic orthostatic hypotension (nOH) | Phase 3 | Data Released | Oral | Neurology |